Comparative Pathology of TRUS Biopsy, Mapping Biopsy and Prostatectomy Specimens Francisco G. La Rosa, MD Associate Professor,

Slides:



Advertisements
Similar presentations
Diffusion-Weighted Imaging in Magnetic Resonance Imaging for prostate gland in Malaysian males with high prostate specific antigen in the diagnosis of.
Advertisements

NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Using Prostate Cryosurgery Cryocare CS ® Technology PM-3592 Rev A 08/11 This information is intended to provide general education for surgeons who have.
THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.
A re-audit of Prostate biopsies from January to December 2010 and Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees.
Grade 1 (almost) never assigned Grade 2 rarely assigned on TURP and RP (exceptionally rare on biopsy)
Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
AJCC TNM Staging 7th Edition Breast Case #3
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.
Steven Joniau Filip Ameye
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System.
Prostate Cancer Screening Assistant Professor Charles Chabert Men’s health Seminar Ballina April 2011 prostates.com.au.
Modern Management of Prostate Cancer With Active Surveillance PROSTATE CANCER SYMPOSIUM NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE SEPTEMBER 10,
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST.
Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.
RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.
Prostate Cancer Prostate cancer is the most common cancer detected in American men. The lifetime risk of a 50-year-old man for latent CaP is 40%; for.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.
Prostate Pathology Emad Raddaoui, MD, FCAP, FASC.
Prostate Pathology Part 1 Francisco G. La Rosa, MD Associate Professor, Department of Pathology University of Colorado Denver, Aurora, Colorado.
Overdetection of prostate cancer ESMO Brussel 2007 Chris H.Bangma Erasmus University Medical Centre Rotterdam, The Netherlands.
Diagnostic Accuracy of Prostate Histoscaning (P005) Arumainayagam N 1, Mikhail M 1, Shamsuddin A 1, Nir D 2, Winkler M 1 1 Charing Cross Hospital, Imperial.
POTENTIAL FOR FAILURE OF FOCAL PROSTATE HEMI-ABLATION STRATEGIES PG O’Malley 1, B Al Hussein Al Awamlh 1, AM Sarkisian 1, DP Nguyen 1, S Jin 1, R Lee 1,
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
“Prostate Cartography”: Targeted &systematic perineal stereotactic prostate biopsy using the BiopSee®platform in locating and re-locating prostate cancer.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Prostate Cancer Screening Risk Management Ben Inch.
Prostate Pathology. Prostate weighs 20 grams in normal adult Retroperitoneal organ,encircling the neck of bladder and urethra Devoid of a distinct capsule.
بسم الله الرحمن الرحيم. The role of three dimensional transrectal ultrasonography (3-D TRUS) and power Doppler sonography in prostatic lesions evaluation.
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
TNM Staging: Prostate TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
Understanding Prostate Myths
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Reference: Robbins & Cotran Pathology and Rubin’s Pathology
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
THE PROSTATE. NORMAL PROSTATE FIBROMUSCU – LAR stroma Glands with EPITHELIUM and BASAL CELLS.
Diseases of the prostate Osvaldo Rubinstein, MD. Normal urinary bladder with right and left ureters.
Manit Arya Consultant Urological Surgeon UCLH and PAH Transforming the Pathway in Prostate Cancer.
Prostate Pathology Sufia Husain. Pathology Department KSU, Riyadh
Prostate Pathology Sufia Husain. Pathology Department KSU, Riyadh
Reference: Robbins & Cotran Pathology and Rubin’s Pathology
Surgical Treatment in Locally Advanced Prostate Cancer
Prostate cancer นพ.ชัชชัย หอมเกตุ.
Prostate Cancer Dr .Gehan Mohamed.
What would you recommend?
Urologist’s Impact on Extended Needle Core Prostate Biopsy Histopathologic Variables within a Single Institution Kashika G. Goyal B.S.1, Joshua J. Ebel.
CONVERSATIONS ON PROSTATE CANCER
Apollo Gleneagles Hospitals,
European Urology Oncology
Figure 3 Semantic model of the active surveillance (AS) timeline
Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer  Arnauld Villers, Philippe Puech, Xavier Leroy, Jacques Biserte,
Volume 72, Issue 3, Pages (September 2017)
Pitfalls of Pathologic Staging in Prostate Cancer
Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI- RADS v2) scoring system in diagnosis of peripheral zone prostate cancer 
Volume 62, Issue 1, Pages (July 2012)
Volume 67, Issue 4, Pages (April 2015)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Treatment Overview: The Multidisciplinary Team
Active Surveillance for Low Risk Prostate Cancer
Prostate Cancer Update
Volume 69, Issue 1, Pages (January 2016)
Computer Simulation of Prostate Biopsies
Presentation transcript:

Comparative Pathology of TRUS Biopsy, Mapping Biopsy and Prostatectomy Specimens Francisco G. La Rosa, MD Associate Professor, Department of Pathology University of Colorado Denver, Aurora, Colorado Targeted Focal Therapy Workshop August 16 – 17, 2012

SAGITAL SECTION OF THE PROSTATE GLAND Seminal Vesicle Central Zone Bladder Peri-urethral zone Anterior Zone Fibro-muscular Peripheral Zone Transition Zone Urethra

CROSS SECTION OF THE PROSTATE FIBROMUSCULAR STROMA anterior PERI-URETHRAL STROMA EJACULATORY DUCTS

HISTORY OF PROSTATE BIOPSY , Ferguson: First described prostate biopsy. Obtained cancer cells by aspirating prostate tissue with an 18-gauge needle transperineally , Astraldi: First transrectal biopsy , Takahashi & Ouchi: First TRUS biopsy , Watanabe: First clinical application of TRUS images ’s Transperineal biopsies

The first sextant prostate needle biopsy scheme was developed by Hodge et al. in 1989 The sextant biopsy scheme consisted of biopsies of the prostate in the midline at the base, mid-gland, and apex. The midline sextant biopsies had a PCa detection rate of 20-30%. However, 25-50% of aggressive PCa remain undetected when using the midline sextant biopsies scheme. J Urol 1989; 142: J Urol 2000; 163: J Urol 2000; 163: Urology 2003; 61: J Urol 1998; 159:

Stamey et al. in 1995 evaluated radical prostatectomy specimens and found that PCa had a higher likelihood of being found in the anterior horns of the peripheral zone and suggested that laterally directed biopsies may provide better detection. Urology 1995; 45: 2-12

Multiple studies have found that directing prostate needle biopsies more laterally increases the PCa detection rates. J Urol 2000; 163: J Urol 2000; 163: Urology 2003; 61:

The current recommendation is an extended-biopsy scheme with at least 8-12 cores including lateral biopsies. Transition zone biopsies are not recommended on initial evaluation. Curr Opin Urol 2004; 14:

It is important to perform both the lateral modified fan- shaped biopsy and the midline sextant biopsies to improve overall PCa detections rates. Thus, we recommend performing midline sextant biopsies, modified fan-shaped biopsy, and transition zone biopsies based on prostate volume, as follows: - 8 biopsies for ≤15 cc - 14 for those >15 cc but ≤50 cc for those >50 cc 1.Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O’Donnell C, Sidhu RS, Sullivan HT, Schulte B, Crawford ED. Optimization of Prostate Cancer Diagnosis by Increasing the Number of Core Biopsies Based on Gland Volume.. Int J Clin Exp Pathol (in press)

TRUS Biopsies

TRANS RECTAL ULTRASOUND (TRUS) GUIDED BIOPSY PROCEDURE

Bad Histology

Good Histology

Peripheral Zone

Central Zone

40X Seminal Vesicles

Mapping Biopsies

Mapping Grid and its relationship with the Prostate

Grid Alignment in perineal area and Rectal Location of Ultrasound Probe

Pathology Report of Mapping Biopsies

3D Reconstruction of Prostate With Location of Cancer Lesions

Watch Video “Mapping Biopsy procedure”

Whole Mount Prostatectomy Specimens

Prostate Cancer: Gross

3-Dimensional Reconstruction of whole- mounted prostatectomy specimens

Venn-diagram representation of activity of patients between positive results from transperineal mapping biopsies (TPMB) and three-dimensional whole-mounted radical prostatectomies (3D-WMRP). (+) indicates presence of prostatic cancer (-) indicates no cancer

- TPMB with a 5-mm grid is an important staging tool that more closely reflects true PCa disease state as found at RP as core TRUSB and other more limited protocols. - TPMB can detect or rule out more aggressive disease, identifying with more accuracy the size and GS of PCa lesions, ensuring that patients are not mistakenly under-treated or unnecessarily over- treated, minimizing treatment-related morbidity.

Case 1 58-year-old man, PSA 4.2 ng/mL,

TRUS guided biopsies Prostate, right: - Prostatic adenocarcinoma, Gleason grade (score = 6) involving <5% of 1 of 12 biopsy core fragments -No evidence of perineural or extra-capsular invasion Prostate, left, fine needle core biopsies (B): - Prostatic adenocarcinoma, Gleason grade (score = 6) involving <5% of 2 of 10 biopsy core fragments - No evidence of perineural or extra-capsular invasion

Radical prostatectomy (after fixation) Length (apex to base) : 3.8 cm Length (apex to base) : 3.8 cm Width (left to right) : 5.2 cm Width (left to right) : 5.2 cm Height (anterior to posterior) : 4.0 cm Height (anterior to posterior) : 4.0 cm Volume: 50.0 mL Volume: 50.0 mL Weight: 50.5 g Weight: 50.5 g Serial whole-mount sections from apex to base of entire prostate and seminal vesicles submitted in (A1-A9), seminal vesicle complex in A10, A11, right seminal vesicle in A12, A13, left seminal vesicle in A14, A15.

Prostate and seminal vesicles, radical prostatectomy: - Prostatic adenocarcinoma, overall Gleason Grade (score = 9) with secondary foci of Gleason grade (score = 6), multifocal and bilateral, involving <5% of prostate (see comments) - Suspicious but not definitive for lymphovascular invasion - Perineural invasion, multifocal - No evidence of extracapsular extension - Seminal vesicles with no evidence of malignancy

Second Opinion Process Urology Clinic Patient (outside diagnostic material) Uropathology (2 nd opinion) Clinical Decision for Therapy Radiology (second opinion) UROLOGIC CANCER SECOND OPINION CONFERENCE Pathology slides returned

UROLOGIC CANCER SECOND OPINION CONFERENCE

The Value of 2 nd Opinion Pathology Diagnosis of Prostate Biopsies Outside pathology report versus 2 nd Opinion in-house versus Whole-Mount Radical Prostatectomy

Second opinion of prostate biopsies Most critical histopathological features: - Gleason Score - Gleason Score (sum of primary plus secondary grades) - Extracapsular extension - Perineural invasion (multifocal) - Identification of HG PIN, ASAP, acute inflammation

# of CasesDiscrepancies (19 %) DIAGNOSIS DISCREPANCIES WITH OUTSIDE CASES 2008 – 2010 (Source: Quality Improvement database, Department of Pathology, UCD)

We found a significant disagreement between outside and in-house primary and secondary Gleason grades (McNemar statistic 6.250, p=0.012) Barqawi AB, Turcanu R, Gamito EJ, Lucia SM, O'Donnell CI, Crawford ED, La Rosa DD, La Rosa FG. The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer. Int J Clin Exp Pathol Jun 20;4(5):

In-house pathologists detected significant features not reported by outside pathologists: i.e. the presence of adipose tissue invasion which is highly suspicious for extraprostatic extension by tumor Barqawi AB, Turcanu R, Gamito EJ, Lucia SM, O'Donnell CI, Crawford ED, La Rosa DD, La Rosa FG. The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer. Int J Clin Exp Pathol Jun 20;4(5):

REPORTING ACUTE INFLAMMATION and BPH RELEVANCE: - Explains increased PSA values in patients negative for PCa - It can help in determining the need for quick repeat biopsies Schatteman PHF, Hoekx L, Wyndaele JJ, Jeuris W, van Marck E. Inflammation in Prostate Biopsies of Men without Prostatic Malignancy or Clinical Prostatitis. Eur Urol 2000;37:

We strongly recommend that a re-evaluation by in-house urologic pathologists should be performed on all outside specimens before patients are admitted for treatment in any institution. Barqawi AB, Turcanu R, Gamito EJ, Lucia SM, O'Donnell CI, Crawford ED, La Rosa DD, La Rosa FG. The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer. Int J Clin Exp Pathol Jun 20;4(5):

Paul Arangua Al Barqawi, MD E. David Crawford, MD Thomas Flaig, MD Eduard Gamito (+) Mark Gallen Michael Glode Kenneth Iczkowski, MD Clifford Jones, DD Francisco G. La Rosa, MD M. Scott Lucia, MD Colin I. O’Donnell Nayana Patel,, MD Susan Sullivan Kathleen Torkko Ruslan Turcanu, MD Departments of Pathology, Surgery, Radiology & Division of Medical Oncology University of Colorado Denver Anschutz Medical Campus School of Medicine Aurora, CO Urology Team